Skip to main

Byram Ozer, MD, PhD

${headerImageAssetTitle}

Background

Byram Ozer, MD, PhD, is a board-certified neurologist and neuro-oncologist who specializes in the management and treatment of primary brain tumors and rare central nervous system (CNS) tumors.

Dr. Ozer is an associate professor in the Department of Hematology and Medical Oncology with a joint appointment in the Department of Neurology at Emory University School of Medicine. He serves as co-director of the Neuro-Oncology Program and director of Translational Research in Neuro-Oncology at Winship Cancer Institute of Emory University.

Before joining Emory, Dr. Ozer was an assistant research physician in the Neuro-Oncology Branch at the National Cancer Institute in Bethesda, Maryland, where he was a member of the NCI-CONNECT program.

Dr. Ozer earned his medical degree and PhD from the University of Wisconsin in Madison. He completed his internship in internal medicine at Good Samaritan Hospital in Cincinnati, Ohio, followed by a neurology residency and neuro-oncology fellowship at the University of California, Los Angeles.

Titles & Roles

  • Associate Professor, Department of Hematology and Medical Oncology
    Emory University School of Medicine
  • Associate Professor, Department of Neurology
    Emory University School of Medicine
  • Co-Director, Neuro-Oncology Program
    Winship Cancer Institute of Emory University
  • Director, Translational Research in Neuro-Oncology
    Winship Cancer Institute of Emory University

Education & Training

Education

  • Fellowship, Neuro-Oncology, 2018
    UCLA Medical Center
  • Residency, Neurology, 2015
    UCLA Medical Center
  • Internship, Internal Medicine, 2012
    Good Samaritan Hospital
  • Medical Education, MD, 2011
    University of Wisconsin School of Medicine and Public Health

Board Certifications

  • Neuro-Oncology
    United Council for Neurological Subspecialties, 2019
  • Neurology
    American Board of Psychiatry and Neurology, 2015

Research

As a physician scientist, Dr. Ozer focuses on developing clinical trials to test emerging and repurposed agents against malignant and rare primary CNS tumors. His specific clinical and research interests include malignant and treatment-refractory meningiomas, ependymomas, medulloblastomas, BRAF-altered CNS tumors and histone-mutated gliomas.

His training in molecular biology informs his translational research goals, which center on understanding tumor and circulating factors related to treatment responses and resistance, as well as developing rational combination therapies. He is also passionate about researching and implementing transitions of care between pediatric and adult practice environments for young adult survivors of pediatric and adolescent primary CNS tumors.

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.